Belimumab Injection (Benlysta)

April 2011
Internal Medicine Alert;4/15/2011, Vol. 33 Issue 7, p53
The article reports on the approval of the treatment for systemic lupus erythematosus (SLE), Belimumab by the U.S. Food and Drug Administration (FDA).


Related Articles

  • FDA Panel Backs HGSI's Benlysta for Lupus. Young, Donna // BioWorld Today;11/17/2010, Vol. 21 Issue 223, p1 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) panel of Benlysta from Human Genome Sciences Inc. as a treatment for adults with systemic lupus erythematosus (SLE). In a 13-2 vote, Benlysta has become the first new lupus treatment in more than 50 years to enter...

  • The discovery and development of belimumab: the anti-BLyS-lupus connection. Stohl, William; Hilbert, David M // Nature Biotechnology;Jan2012, Vol. 30 Issue 1, p69 

    For the first time in more than 50 years, the US Food and Drug Administration has approved a drug specifically for the treatment of systemic lupus erythematosus (SLE). This drug, belimumab (Benlysta), is a human monoclonal antibody that neutralizes the B-cell survival factor, B-lymphocyte...

  • New Reports by BioTrends Provide Insight into the Management of Patients with Systemic Lupus Erythematosus and Benchmark the Launch of BENLYSTA against Other Recent Product Launches.  // Biomedical Market Newsletter;6/9/2011, p397 

    The article focuses on the findings by BioTrends Research Group LLC which reveal high enthusiasm for the BENLYSTA drug of GlaxoSmithKline and Human Genome Sciences Inc. It states that BENLYSTA is the first product to obtain U.S. Food and Drug Administration (FDA) approval for use in systemic...

  • FDA actions. Elliott, William T. // Primary Care Reports;May2011 Pharmacology Watch, p2 

    This section offers news briefs from the U.S. Food & Drug Administration (FDA). Belimumab has been approved for the treatment of patients with lupus and is marketed as Benlysta by GlaxoSmithKline. Roflumilast, marketed as Daliresp by Forest Pharmaceuticals, has been cleared for patients with...

  • FDA arthritis advisory committee votes 13-2 in favor of approving lupus biologic drug. Kassan, Stuart S.; Rapp, Susan M. // Orthopedics Today;Dec2010, Vol. 30 Issue 12, p56 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to support the biologic license application for the belimumab drug.

  • Development of an FDA guidance document for clinical trials in SLE. Siegel, J N // Lupus;1999, Vol. 8 Issue 8, p581 

    To make the process of developing new therapeutic agents more efficient, it is critical that investigators and industry sponsors understand in advance what information they will need to provide to the US Food and Drug Administration (FDA) in order to license and market their product. To...

  • Methodologic Issues in the Validation of Putative Biomarkers and Surrogate Endpoints in Treatment Evaluation for Systemic Lupus Erythematosus. Liang, Matthew H.; Simard, Julia F.; Costenbader, Karen; Dore, Benjamin T.; Ward, Michael; Fortin, Paul R.; Illei, Gabor G.; Manzi, Susan; Mittleman, Barbara; Buyon, Jill; Gupta, Samardeep; Abrahamowicz, Michal // Endocrine, Metabolic & Immune Disorders - Drug Targets;Mar2009, Vol. 9 Issue 1, p108 

    No new drugs have been approved for the treatment of systemic lupus erythematosus (SLE) by the Food and Drug Administration for the last 30 years. One barrier has been the lack of validated biomarkers and surrogate endpoints. Validation of SLE biomarkers in the past have been methodologically...

  • GSK, HGS cleared to launch broad label lupus drug. Iskowitz, Marc // Medical Marketing & Media;Apr2011, Vol. 46 Issue 4, p8 

    The article reports on the launch of the drug Benlysta by Human Genome Sciences Inc. (HSG) and GlaxoSmithKline (GSK) in the U.S. It states that the drug is indicated for patients with systemic lupus erythematosus (SLE). It mentions that the drug has been approved by the U.S. Food and Drug...

  • Ending the 50-Year Drought of FDA Drug Approval for SLE. Merrill, Joan T. // Bulletin of the NYU Hospital for Joint Diseases;2011, Vol. 69 Issue 3, p238 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics